查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553533

美國避孕藥具市場規模、佔有率和趨勢分析：按產品和細分市場預測（2024-2030）

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 113 Pages | 商品交期: 2-10個工作天內

價格

美國避孕市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國避孕藥具市場規模預計將達到124.6億美元，2024年至2030年複合年成長率預計為5.20%。

在美國，避孕器具的供應量有所增加，對社會各個方面產生了積極影響，包括婦女的教育、職業機會和貧困水平。現代避孕方法的出現極大地改善了女性的職業前景，並使她們能夠獲得與男性同等的工資。此外，由於意外懷孕和撫養孩子的經濟負擔而陷入貧困的婦女人數也減少了。

計劃生育服務的合法化和提供有助於減少貧困和改善子孫後代的經濟狀況。計劃生育計畫可以改善婦女和兒童的健康狀況，並間接支持經濟安全。能夠控制自己生殖健康的婦女更有可能參與勞動力隊伍並為家庭收入做出貢獻，從而進一步降低貧困水平。

2023 年 6 月，拜登-哈里斯政府宣布與<官民合作關係>。該舉措旨在解決美國各地女性日益擴大的健康差距問題。拜登-哈里斯政府致力於加強國際計劃生育工作，特別是在避孕器使用率低、孕產婦死亡率高的西非。 2023會計年度將額外撥款1,550萬美元，總合8,650萬美元，旨在改善九個法語國家的性健康和生殖健康保健。

此外，COVID-19 大流行對美國醫療保健產業產生了重大影響。默克公司等避孕器具製造商報告稱，由於醫療保健提供者優先考慮 COVID-19 患者，對避孕植入Nexplanon 的需求有所下降。然而，疫苗接種的增加和 COVID-19 患者負擔的減輕導致服用避孕藥具的醫生就診次數回升，從而促進了產品需求。由於長效避孕藥和非荷爾蒙避孕藥的便利性、避孕功效長效且無副作用，預計未來幾年對長效避孕藥和非荷爾蒙避孕藥的需求將會增加。

美國避孕藥具市場報告要點：

  • 從產品來看，藥丸由於使用方便且容易取得，佔據了最大的市場佔有率。由於學名藥的存在，該國的避孕藥具市場競爭非常激烈。
  • 市場上企業的經營受到學名藥競爭、行業重組、競品合併、已上市產品臨床試驗的新資訊以及競爭對手新產品獲得專利的影響。
  • 由於年輕女性希望避免與荷爾蒙避孕藥相關的風險，對非荷爾蒙避孕藥的需求預計將會增加。新開發的產品，如非荷爾蒙避孕環、隔膜和創新保險套預計將有助於非荷爾蒙產品領域在預測期內的成長。
  • 2024年4月，Opil美國FDA核准了第一個口服避孕藥OTC藥丸，開始在包括Walgreens、CVS和Walmart在內的大多數零售藥局銷售。該產品也可在 CVS Pharmacy 應用程式、CVS.com 以及美國各地 7,500 多家 CVS Pharmacy 商店購買。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢及展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 行業機會
    • 產業挑戰
  • 監管和報銷框架
  • 管道分析
  • COVID-19 的影響：定性分析
  • 商業環境分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國避孕市場：依產品（2018-2030）

  • 美國避孕市場：產品細分儀表板
  • 2023年及2030年產品趨勢及市場佔有率分析
  • 美國避孕藥具市場規模及預測：依產品分類（2018-2030）
  • 丸
    • 丸劑市場（2018-2030）
    • 子宮內避孕器 (IUD)
  • 保險套
    • 安全套市場（2018-2030）
    • 男用保險套
  • 避孕環
    • 避孕環市場（2018-2030）
  • 皮下植入
    • 皮下植入市場（2018-2030）
  • 注射
    • 注射藥品市場（2018-2030）
  • 其他
    • 其他市場（2018-2030）

第5章競爭狀況

  • 主要市場參與企業的最新趨勢和影響分析
  • 主要交易及策略聯盟分析
  • 供應商情況
  • 參與企業概況
  • 財務表現
  • 產品基準
  • 公司分類
  • 公司市場分析
  • 策略規劃
  • 公司簡介/上市公司
Product Code: GVR-2-68038-702-5

U.S. Contraceptive Market Growth & Trends:

The U.S. contraceptive market size is anticipated to reach USD 12.46 billion by 2030 and is projected to grow at a CAGR of 5.20% from 2024 - 2030, according to a new report by Grand View Research, Inc. The growing availability of contraceptives in the United States has positively influenced various societal aspects, including education, career opportunities, and poverty levels among women. Access to modern contraceptive methods has significantly enhanced women's career prospects, enabling them to earn wages comparable to their male counterparts. In addition, it has resulted in a decrease in the number of women experiencing poverty due to unplanned pregnancies and the financial burdens associated with raising children.

The legalization and access to family planning services have contributed to reducing poverty and improving economic conditions for future generations. Family planning programs have been linked to improved health outcomes for women and children, which indirectly support economic stability. Women who can control their reproductive health are more likely to participate in the workforce and contribute to household income, further reducing poverty levels.

In June 2023, The Biden-Harris Administration launched a new public-private partnership between the U.S. Department of Health and Human Services (HHS) to enhance access to contraception, which is a crucial aspect of reproductive health. This initiative seeks to tackle the increasing disparities in women's health across the United States. The Biden-Harris Administration is committed to enhancing international family planning efforts, particularly in West Africa, where contraceptive use is low and maternal mortality rates are high. An additional USD 15.5 million has been allocated for fiscal year 2023, bringing the total to USD 86.5 million aimed at improving sexual and reproductive health care in nine Francophone countries.

Furthermore, the COVID-19 pandemic has significantly impacted the U.S. healthcare sector. Contraceptive manufacturers, such as Merck & Co., reported a reduction in demand for the contraceptive implant Nexplanon due to the prioritization of COVID-19 patients by healthcare providers. However, an increase in vaccination and reduced burden of COVID-19 patients helped restore the physician office visits for contraceptive administration, in turn contributing to product demand. Demand for long-acting and nonhormonal contraceptives is expected to increase in the coming years due to convenience, long-term protection, and fewer side effects demonstrated by these contraceptives.

U.S. Contraceptive Market Report Highlights:

  • In terms of product, the pills segment held the largest market share owing to the convenience of use and easy availability. The contraceptive pills market in the country is highly competitive due to the presence of generic products.
  • The operations of market players are affected by generic competition, industry consolidation, competitive combination products, new information from clinical trials of marketed products, and patents granted to competitors' new products, among others.
  • The demand for nonhormonal contraceptives in young women is expected to increase as they want to avoid risks associated with hormonal contraceptives. Newly developed products, such as nonhormonal vaginal rings, diaphragms, and innovative condoms, are expected to aid the growth of nonhormonal products segment during the forecast period.
  • In April 2024, the Opill U.S. FDA approved the first oral contraceptive OTC pill, which began selling at most stores in retail pharmacies such as Walgreens, CVS, and Walmart. The product is also offered at CVS Pharmacy app and CVS.com and more than 7,500 CVS Pharmacy stores in the U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Estimates and Forecast Timeline
  • 1.2. Market Definitions
    • 1.2.1. Segment definitions
      • 1.2.1.1. Product
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
      • 1.4.4.1. Details of Primary Research
    • 1.4.5. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Approach 1: Commodity flow analysis
    • 1.7.2. Approach 2: Volume Price Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
    • 2.2.1. Product
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Rapid technological advancements
      • 3.3.1.2. Increasing initiatives by social organizations to improve access to condoms
      • 3.3.1.3. Rising publicly funded family planning services
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Increasing geriatric population and rising prevalence of infertility
      • 3.3.2.2. Adverse effects associated with use of contraceptive drugs and devices
    • 3.3.3. Industry Opportunities
    • 3.3.4. Industry Challenges
  • 3.4. Regulatory and Reimbursement Framework
  • 3.5. Pipeline Analysis
  • 3.6. Impact of COVID-19: Qualitative Analysis
  • 3.7. Business Environment Analysis Tools
    • 3.7.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.7.1.1. Supplier power
      • 3.7.1.2. Buyer power
      • 3.7.1.3. Substitution threat
      • 3.7.1.4. Threat of new entrant
      • 3.7.1.5. Competitive rivalry
    • 3.7.2. PESTEL Analysis

Chapter 4. U.S. Contraceptive Market, By Product, 2018 - 2030 (USD Million)

  • 4.1. U.S. Contraceptive Market: Product Segment Dashboard
  • 4.2. Product Movement & Market Share Analysis, 2023 & 2030
  • 4.3. U.S. Contraceptive Market Size & Forecast and Forecasts, By Product, 2018 - 2030 (USD Million)
  • 4.4. Pills
    • 4.4.1. Pills market, 2018 - 2030 (USD Million)
    • 4.4.2. Intrauterine Device (IUD)
      • 4.4.2.1. Intrauterine Device (IUD) market, 2018 - 2030 (USD Million)
      • 4.4.2.2. Hormonal IUD
        • 4.4.2.2.1. Hormonal IUD market, 2018 - 2030 (USD Million)
      • 4.4.2.3. Nonhormonal IUD
        • 4.4.2.3.1. Nonhormonal IUD market, 2018 - 2030 (USD Million)
  • 4.5. Condoms
    • 4.5.1. Condoms market, 2018 - 2030 (USD Million)
    • 4.5.2. Male Condoms
      • 4.5.2.1. Male condoms market, 2018 - 2030 (USD Million)
      • 4.5.2.2. Female condoms
        • 4.5.2.2.1. Female condoms market, 2018 - 2030 (USD Million)
  • 4.6. Vaginal Ring
    • 4.6.1. Vaginal ring market, 2018 - 2030 (USD Million)
  • 4.7. Subdermal Implants
    • 4.7.1. Subdermal implants market, 2018 - 2030 (USD Million)
  • 4.8. Injectable
    • 4.8.1. Injectable market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, by Key Market Participants
  • 5.2. Major Deals & Strategic Alliances Analysis
    • 5.2.1. Mergers & acquisitions and joint ventures
    • 5.2.2. Licensing & partnership and technology collaborations
  • 5.3. Vendor Landscape
    • 5.3.1. List of Players in the U.S. Contraceptive Market
    • 5.3.2. Company Market Position Analysis
  • 5.4. Participant's overview
  • 5.5. Financial Performance
  • 5.6. Product Benchmarking
  • 5.7. Company Categorization
  • 5.8. Company Market Position Analysis
  • 5.9. Strategy Mapping
    • 5.9.1. Expansion
    • 5.9.2. Acquisition
    • 5.9.3. Collaborations
    • 5.9.4. Others
  • 5.10. Company Profiles/Listing
    • 5.10.1. Church & Dwight Co., Inc.
      • 5.10.1.1. Overview
      • 5.10.1.2. Financial Performance
      • 5.10.1.3. Product Benchmarking
      • 5.10.1.4. Strategic Initiatives
    • 5.10.2. Reckitt Benckiser Group plc
      • 5.10.2.1. Overview
      • 5.10.2.2. Financial Performance
      • 5.10.2.3. Product Benchmarking
      • 5.10.2.4. Strategic Initiatives
    • 5.10.3. Veru, Inc.
      • 5.10.3.1. Overview
      • 5.10.3.2. Financial Performance
      • 5.10.3.3. Product Benchmarking
      • 5.10.3.4. Strategic Initiatives
    • 5.10.4. Organon Group of Companies
      • 5.10.4.1. Overview
      • 5.10.4.2. Financial Performance
      • 5.10.4.3. Product Benchmarking
      • 5.10.4.4. Strategic Initiatives
    • 5.10.5. Pfizer, Inc.
      • 5.10.5.1. Overview
      • 5.10.5.2. Financial Performance
      • 5.10.5.3. Product Benchmarking
      • 5.10.5.4. Strategic Initiatives
    • 5.10.6. Teva Pharmaceutical Industries Ltd.
      • 5.10.6.1. Overview
      • 5.10.6.2. Financial Performance
      • 5.10.6.3. Product Benchmarking
      • 5.10.6.4. Strategic Initiatives
    • 5.10.7. The Cooper Companies, Inc.
      • 5.10.7.1. Overview
      • 5.10.7.2. Financial Performance
      • 5.10.7.3. Product Benchmarking
      • 5.10.7.4. Strategic Initiatives
    • 5.10.8. Mayer Laboratories, Inc.
      • 5.10.8.1. Overview
      • 5.10.8.2. Financial Performance
      • 5.10.8.3. Product Benchmarking
      • 5.10.8.4. Strategic Initiatives
    • 5.10.9. Agile Therapeutics
      • 5.10.9.1. Overview
      • 5.10.9.2. Financial Performance
      • 5.10.9.3. Product Benchmarking
      • 5.10.9.4. Strategic Initiatives
    • 5.10.10. TherapeuticsMD, Inc.
      • 5.10.10.1. Overview
      • 5.10.10.2. Financial Performance
      • 5.10.10.3. Product Benchmarking
      • 5.10.10.4. Strategic Initiatives
    • 5.10.11. Bayer AG
      • 5.10.11.1. Overview
      • 5.10.11.2. Financial Performance
      • 5.10.11.3. Product Benchmarking
      • 5.10.11.4. Strategic Initiatives
    • 5.10.12. Afaxys, Inc.
      • 5.10.12.1. Overview
      • 5.10.12.2. Financial Performance
      • 5.10.12.3. Product Benchmarking
      • 5.10.12.4. Strategic Initiatives
    • 5.10.13. Mithra Pharmaceuticals
      • 5.10.13.1. Overview
      • 5.10.13.2. Financial Performance
      • 5.10.13.3. Product Benchmarking
      • 5.10.13.4. Strategic Initiatives
    • 5.10.14. Abbvie
      • 5.10.14.1. Overview
      • 5.10.14.2. Financial Performance
      • 5.10.14.3. Product Benchmarking
      • 5.10.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Contraceptive methods and associated side effects
  • Table 4 Classification of contraceptives by the U.S. FDA
  • Table 5 States that have expanded contraceptive coverage guarantee in the Affordable Care Act
  • Table 6 Types of oral contraceptives, composition, and regimen
  • Table 7 List of intrauterine devices currently available in the U.S.
  • Table 8 Types of male condom variants
  • Table 9 US contraceptive market revenue estimates and forecast, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. contraceptive market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. contraceptive market: Parent market outlook
  • Fig. 13 U.S. contraceptive market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. contraceptive market: Porter's five forces analysis
  • Fig. 17 U.S. contraceptive market: PESTLE analysis
  • Fig. 18 U.S. contraceptive market: product segment dashboard
  • Fig. 19 U.S. contraceptive market: product market share analysis, 2023 & 2030
  • Fig. 20 Pills market, 2018 - 2030 (USD Million)
  • Fig. 21 Intrauterine Devices (IUD) market, 2018 - 2030 (USD Million)
  • Fig. 22 Hormonal IUD market, 2018 - 2030 (USD Million)
  • Fig. 23 Nonhormonal IUD market, 2018 - 2030 (USD Million)
  • Fig. 24 Condoms market, 2018 - 2030 (USD Million)
  • Fig. 25 Male condoms market, 2018 - 2030 (USD Million)
  • Fig. 26 Female condoms market, 2018 - 2030 (USD Million)
  • Fig. 27 Vaginal ring market, 2018 - 2030 (USD Million)
  • Fig. 28 Subdermal implants market, 2018 - 2030 (USD Million)
  • Fig. 29 Injectable market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Company/competition categorization
  • Fig. 32 Company market position analysis
  • Fig. 33 U.S. contraceptive market: Strategy mapping